A comparison of abciximab use in MCO and non-MCO populations

American Journal of Managed Care

Volumn 7, Issue 1, 2001, Pages 53-62

  Lage, M J ^a   Barber, B L ^a   Bala, M ^a   Ball, D E ^a   Bowman, L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB;

ADULT; AGED; ARTICLE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DEMOGRAPHY; DRUG COST; DRUG USE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; ISCHEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MINORITY GROUP; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; ANGINA PECTORIS; ANGIOPLASTY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DRUG UTILIZATION REVIEW; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LENGTH OF STAY; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 0035142588     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Evolution, growth, and status of managed care in the United States
2. The relationship between hospital length of stay and rate of death in heart failure
3. Care of acute myocardial infarction by non-invasive and invasive cardiologists: Procedure use, cost, and outcome
4. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary sapheneous vein grafts
5. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and 6-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction
6. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
7. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention
8. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
9. Sustained suppression of ischemic complications of coronary interventions by platelet GP IIb/IIIa blockade with abciximab: One year outcome in the EPILOG trial
10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein-IIb/IIIa blockade
11. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina
12. Generalized models with selectivity
13. Sample selection bias as a specification error
14. Health care costs and outcomes: How should we evaluate real world data?
15. Estimating endogeneous treatment effects in retrospective data analysis
16. Methods for using large databases in health care research: Problems and promises. Proceedings of the Third Bienniel Regenstrief Conference
17. SSRI antidepressant selection and concomitant prescribing of anxiolytics and sedative-hypnotics: Evidence from primary care in the United Kingdom
18. Shorter hospital stays for angioplasty patients who receive abciximab
19. Comorbidity as a correlate of length of stay for hospitalized patients with acute chest pain
20. Analyzing intensive care unit length of stay data: Problems and possible solutions
21. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty: Clinical and procedural predictors
22. Cardiac operations in patients aged 70 years and over: Mortality, length of stay, and hospital charge
23. Refinement of the Medicare diagnosis-related groups to incorporate a measure of severity
24. Gender, racial, and geographic differences in the performance of cardiac diagnostic and therapeutic procedures for hospitalized acute myocardial infarction in four states
25. Differences in the use of procedures between women and men hospitalized for coronary heart disease
26. Sex differences in the management of coronary artery disease
27. Long-term implications of racial differences in the use of revascularization procedures (the Myocardial Infarction Triage and Intervention Registry)
28. Racial variation in cardiac procedure use and survival following myocardial infarction in the Department of Veterans Affairs
29. Racial differences in the use of revascularization procedures after coronary angioplasty
30. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts
31. Confidence in HMOs sink, but Congress is still offering placebos
32. Regional variation across the United States in the management of acute myocardial infarction
33. Cardiology and the quality of medical practice
34. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
35. An overview of the results of the EPIC trial
36. Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent use, clinical outcomes, and bleeding complications
37. Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study
38. Abciximab therapy in percutaneous intervention: Economic issues in the United States
39. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables
40. Small area variations in hospitalization rates: How much you see depends on how you look
41. Costs and effects of c7E3 in high risk PCI patients: An indirect analysis for the Netherlands
42. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization